| [1] |
Hance KW,Anderson WF,Devesa SS,et al.Trends in inflammatory breast carcinoma incidence and survival:the Surveillance,Epidemiology and End Results programat National Cancer Institute.J Natl Cancer Inst,2005,97:966-975.
|
| [2] |
Yang WT,Le Petross HT,Macapinlac H,et al.Inflammatory breast cancer:PET/CT,MRI,mammography,and sonography findings.Breast Cancer Res Treat,2008,109:417-426.
|
| [3] |
Anderson WF,Chu KC,Chang S,et al.Inflammatory breast carcinoma and noninflammatory locally advanced breast carcinomas:distinct clinicopathologic entities?J Clin Oncol,2003,21:2254-2259.
|
| [4] |
Lê MG,Arriagada R,Bahi J,et al.Are risk factors for breast cancer si milar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer? Breast,2006,15:355-362.
|
| [5] |
Colpaert CG,Verr meulen PB,Benoy I,et al.Inflammatory breast cancer shows angiogenesis with high endothelial proliferation rate and strong E-cadherin expression.Br J Cancer,2003,88:718-725.
|
| [6] |
Tomlinson JS,Alpaugh ML,Barsky SH,et al.An intact overexpressed E-cadherin/alpha,beta-catenin axis characterizes the ly mphovascular emboli of inflammatory breast carcinoma.Cancer Res,2001,61:5231-5241.
|
| [7] |
Alpaugh ML,Tomlinson JS,Ye Y,et al.Relationship of sialyl-Lewis(x/a)underexpression and Ecadherin overexpression in the ly mphovascular embolus of inflammatory breast carcinoma.Am J Pathol,2002,161:619-628.
|
| [8] |
Bieche I,Lerebours F,Tozlu S,et al.Molecular profiling of inflammatory breast cancer:identification of a poor-prognosis gene expression signature.Clin Cancer Res,2004,10:6789-6795.
|
| [9] |
Van der Auwera I,Van Laere SJ,Van den Eynden GG,et al.Increased angiogenesis and ly mphangiogenesis in inflammatory versus noninflammatory breast cancer by real-ti me reverse transcriptase-PCR gene expression quantification.Clin Cancer Res,2004,10:7965-7971.
|
| [10] |
He Y,Rajantie I,Pajusola K,et al.Vascular endothelial cell growth factor receptor 3-mediated activation of ly mphatic endotheliu m is crucial for tu mor cell entry and spread via ly mphatic vessels.Cancer Res,2005,65:4739-4746.
|
| [11] |
Kleer CG,Griffith KA,Sabel MS,et al.RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcino mas of the breast.Breast Cancer Res Treat,2005,93:101-110.
|
| [12] |
Kleer CG,Zhang Y,Pan Q,et al.WISP3 and RhoC guanosine triphosphatase cooperate in the develop ment of inflammatory breast cancer.Breast Cancer Res,2004,6:R110-R115.
|
| [13] |
Van Laere S,Van der Auwera I,Van den Eynden G,et al.Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affy metrix-based genome-wide gene-expression analysis.Br J Cancer,2007,97:165-174.
|
| [14] |
Van Laere SJ,Van der Auwera I,Van den Eynden GG,et al.NF-kappaB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation,secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation.Br J Cancer,2007,97:659-669.
|
| [15] |
Xiao Y,Ye Y,Yearsley K,et al.Thely mphovascular embolus of inflammatory breast cancer expresses a stemcell-like phenotype.Am J Pathol,2008,173:561-574.
|
| [16] |
Shirakawa K,Tsuda H,Heike Y,et al.Absence of endothelial cells,central necrosis,and fibrosis are associated with aggressive inflammatory breast cancer.Cancer Res,2001,61:445-451.
|
| [17] |
Lerebours F,Bieche I,Lidereau R.Update on inflammatory breast cancer.Breast Cancer Res,2005,7:52-58.
|
| [18] |
Hennessy BT,Gonzalez Angulo AM,Hortobagyi GN,et al.Disease-free and overall survival after pathological co mplete disease remission of cytologically proven inflammatory breast carcinoma axillary ly mph node metastases after pri mary systemic chemotherapy.Cancer,2006,106:1000-1006.
|
| [19] |
Cristofanilli M,Valero V,Buzdar AU,et al.Inflammatory breast cancer(IBC)and patterns of recurrence:understanding the biology of a unique disease.Cancer,2007,110:1436-1444.
|
| [20] |
Yalamanchili K,Lal muanpuii J,Waheed F,et al.High-dose chemotherapy with autologous stem cell rescue in stageIIIBinflammatory breast cancer.Anticancer Research,2008,28:3139-142.
|
| [21] |
So mlo G,Frankel P,Chow W,et al.Prognostic indicators and survival in patients with stage IIIB inflammatory breast carcinoma after dose-intense chemotherapy.J Clin Oncol,2004,22:1839-1848.
|
| [22] |
von Minckwitz G,Sinn HP,Raab G,et al.Clinical response after t wo cycles compared to HER-2,Ki-67,p53,and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast.Breast Cancer Res,2008,10:1-11.
|
| [23] |
Mina L,Soule SE,Badve S,et al.Predicting response to pri mary chemotherapy:gene expression profiling of paraffin-embedded core biopsy tissue.Breast Cancer Res Treat,2007,103:197-208.
|
| [24] |
Hurley J,Doliny P,Reis I,et al.Docetaxel,cisplatin,and trastuzu mab as pri mary systemic therapy for hu man epider mal growth factor receptor 2-positive locally advanced breast cancer.J Clin Oncol,2006,24:1831-1838.
|
| [25] |
Baselga J,Semiglazo V,Manikhas GM,et al.Efficacy of neoadjuvant trastuzu mab in patients with inflammatory breast cancer:datafromthe NOAH(Neoadjuvant Herceptin)phaseⅢtrial.Eur J Cancer Suppl,2007,5:193.
|
| [26] |
Kauf man B,Trudeau M,Awada A,et al.Lapatinib monotherapy in patients with HER-2-overexpressing relapsed or refractory inflammatory breast cancer:final results and survival of the expanded HER-2+cohort in EGF103009,a phaseⅡstudy.Lancet Oncol,2009,4:581-588.
|
| [27] |
Cristofanilli M,Boussen H,Baselga J,et al.A phaseⅡcombination study of lapatinib and paclitaxel as a neoadjuvant therapy in patients with newly diagnosed inflammatory breast cancer(IBC).Breast Cancer Res Treat,2006,100:s5.
|
| [28] |
Hidar S,Bibi M,Gharbi O,et al.Sentinel ly mph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancer.Int J Surg,2009,2:1-7.
|
| [29] |
Davis JT,Brill YM,Si mmon S,et al.Ultrasound-guided fine-needle aspiration of clinically negative ly mph nodes versus sentinel node mapping in patients at high risk for axillary metastasis.Ann Surg Oncol,2006,13:1545-1552.
|
| [30] |
Singletary SE.Surgical management of inflammatory breast cancer.Semin Oncol,2008,35:72-77.oncology consideration.Ann Surg Oncol,2002,9:820-821.
|